Semperit earnings fall 70% on high costs, gloves decline
17 Aug 2022
Share:
Austrian rubber group says medical sector divestment “coming back into focus”
Vienna – Semperit Group has recorded a sharp drop in earnings in the first half of 2022, amid increasing costs pressure and a sharp drop within its glove-manufacturing medical business – Sempermed.
First half earnings (EBITDA) declined 70% to €75 million, on 14% lower sales of €570 million, which was driven by “the expected slump in the medical business,” the Austrian group reported 17 Aug.
During the period, the Industrial Sector – which includes Semperflex, Sempertrans, Semperform and Semperseal – achieved strong 64% increase in earnings to €68 million on 39% higher sales of €372.3 million.
This, Semperit said, was primarily due to the increase in average sales prices in all segments, which enabled the ‘quick’ passing through of raw material and energy price increases.
By contrast, the medical sector reported a 93% decline in earnings to €15.6 million, as sales fell 50% to €198.3 million.
Semperit linked the decline to a sharp fall in price levels following the end of the boom in demand for medical protective gloves.
Average sales prices in the first half of the year were still above the pre-coronavirus level, said Semperit, adding that prices continue to fall.
Operating results for the period were burdened by significant cost increases and the medical unit’s “return to normality” following two years of strong performance.
For the full year outlook, Semperit said it expected “a significantly weaker result” for the second half of 2022, confirming the guidance published in March.
The Austrian group is also ‘bring back into focus’ plans to divest its medical business, a decision made in January 2020 and put on-hold during the Covid high demand.
Semperit said the second half of the year is generally the weaker half for the group due to seasonal cyclicality.
“Regularly planned maintenance and plant closures in summer and Christmas reinforce this effect,” it added.
In the medical sector, the easing of Covid, the fast-than-expected return to buyer’s market, and overcapacity caused by global expansions will mean “a significantly weaker contribution” which will burden the group results.
Furthermore, the Vienna-based group also anticipates annual results to be influenced by developments such as the Russia-Ukraine war, and particularly the risk of sanctions on special raw materials and consumables which are necessary for the production of vulcanised rubber products.
In addition, price increases for raw materials, Europe’s energy crisis and road freight woes will likely influence the group’s annual performance.
This article is only available to subscribers - subscribe today
Subscribe for unlimited access. A subscription to European Rubber Journal includes:
Every issue of European Rubber Journal (6 issues) including Special Reports & Maps.
Unlimited access to ERJ articles online
Daily email newsletter – the latest news direct to your inbox